{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:06:50Z","timestamp":1793390810393,"version":"4.5.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T00:00:00Z","timestamp":1622419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T00:00:00Z","timestamp":1622419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s40272-021-00452-4","type":"journal-article","created":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T03:13:41Z","timestamp":1622430821000},"page":"411-415","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Mirabegron: Pediatric First Approval"],"prefix":"10.1007","volume":"23","author":[{"given":"Susan J.","family":"Keam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,31]]},"reference":[{"key":"452_CR1","unstructured":"US Food and Drug Administration. FDA approves new indication for drug to treat neurogenic detrusor overactivity in pediatric patients [media release]. 25 Mar 2021. https:\/\/www.fda.gov\/."},{"issue":"5","key":"452_CR2","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40272-017-0249-x","volume":"19","author":"P Kroll","year":"2017","unstructured":"Kroll P. Pharmacotherapy for pediatric neurogenic bladder. Pediatr Drugs. 2017;19(5):463\u201378.","journal-title":"Pediatr Drugs"},{"issue":"2","key":"452_CR3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s11884-018-0465-4","volume":"13","author":"DC Snow-Lisy","year":"2018","unstructured":"Snow-Lisy DC. Management of overactive bladder in children. Curr Bladder Dysfunct Rep. 2018;13(2):38\u201345.","journal-title":"Curr Bladder Dysfunct Rep."},{"key":"452_CR4","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s11884-016-0371-6","volume":"11","author":"RM Sturm","year":"2016","unstructured":"Sturm RM, Cheng EY. The management of the pediatric neurogenic bladder. Curr Bladder Dysfunct Rep. 2016;11:225\u201333.","journal-title":"Curr Bladder Dysfunct Rep."},{"key":"452_CR5","unstructured":"Astellas Pharma. MYRBETRIQ\u00ae\/MYRBETRIQ\u00ae granules: US prescribing information. 2021. https:\/\/astellas.us\/docs\/Myrbetriq_WPI.pdf. Accessed 12 Apr 2021."},{"key":"452_CR6","unstructured":"Astellas Pharma. FDA accepts for priority review the New Drug Application for mirabegron for oral suspension and supplemental new drug application for Myrbetriq\u00ae (mirabegron) tablets in pediatric patients [media release]. 6 Jan 2021. http:\/\/www.astellas.com."},{"key":"452_CR7","unstructured":"Astellas Pharma. Astellas garners new indication new product formulation approvals from U.S. FDA for children with neurogenic detrusor overactivity (NDO) [media release]. 26 Mar 2021. http:\/\/www.astellas.com."},{"key":"452_CR8","unstructured":"ClinicalTrials.gov. Open-label phase 3 study with mirabegron in children from 3 to less than 18 years of age with neurogenic detrusor overactivity (Crocodile). 2020. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02751931?term=mirabegron&cond=neurogenic+detrusor+overactivity&draw=2&rank=1. Accessed 15 Apr 2021."},{"key":"452_CR9","doi-asserted-by":"crossref","unstructured":"Rittig S, Baka-Ostrowska M, Tondel C, et al. The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model-based pediatric dose estimation. J Pediatr Urol. 2020;16(1):31.e1\u201310.","DOI":"10.1016\/j.jpurol.2019.10.009"},{"issue":"8","key":"452_CR10","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1007\/s00345-018-2576-0","volume":"37","author":"JS Park","year":"2019","unstructured":"Park JS, Lee YS, Lee CN, et al. Efficacy and safety of mirabegron, a beta3-adrenoceptor agonist, for treating neurogenic bladder in pediatric patients with spina bifida: a retrospective pilot study. World J Urol. 2019;37(8):1665\u201370.","journal-title":"World J Urol."},{"key":"452_CR11","doi-asserted-by":"crossref","unstructured":"Sager C, Sanmartino M, Burek C, et al. Efficacy and safety of mirabegron as adjuvant treatment in children with refractory neurogenic bladder dysfunction. J Pediatr Urol. 2020;16(5):655.e1\u20136.","DOI":"10.1016\/j.jpurol.2020.07.020"},{"issue":"1","key":"452_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.eururo.2016.02.007","volume":"70","author":"AS Blais","year":"2016","unstructured":"Blais AS, Nadeau G, Moore K, et al. Prospective pilot study of mirabegron in pediatric patients with overactive bladder. Eur Urol. 2016;70(1):9\u201313.","journal-title":"Eur Urol."},{"issue":"4","key":"452_CR13","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.juro.2016.11.101","volume":"197","author":"F Morin","year":"2017","unstructured":"Morin F, Blais AS, Nadeau G, et al. Dual therapy for refractory overactive bladder in children: a prospective open-label study. J Urol. 2017;197(4):1158\u201363.","journal-title":"J Urol."}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-021-00452-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-021-00452-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-021-00452-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T02:36:56Z","timestamp":1626143816000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-021-00452-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,31]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["452"],"URL":"https:\/\/doi.org\/10.1007\/s40272-021-00452-4","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,31]]},"assertion":[{"value":"31 May 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Susan J. Keam is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}